AdaptHealth Analyst Price Targets - Benzinga

AdaptHealth Corp

AHCONASDAQ

Trade with Public

Trade with Public

$7.42

1.1418.15%

Últ. Act.: Nov 4, 1:55 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

AdaptHealth Analyst Price Targets - Benzinga

AdaptHealth Analyst Price Targets

Wall Street analyst price targets and consensus rating for AdaptHealth (AHCO).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Sell

Consensus RatingBuy# Analysts8Avg. Consensus PT$11Upside to Avg. PT+41.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$10→$9
Aug 6, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$14→$10
Aug 6, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$15→$8
Aug 5, 2026	Truist Securities	David Macdonald	PT Cut	Buy	$14→$9
Jul 21, 2026	Jefferies	Brian Tanquilut	Upgrade	Hold→Buy	$11→$13
Jul 6, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$18→$15
May 11, 2026	RBC Capital	Ben Hendrix	PT Raise	Outperform	$13→$15
May 6, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$14→$16
May 6, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$15→$14
Apr 13, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$13→$14
Feb 26, 2026	Leerink Partners	Whit Mayo	PT Cut	Outperform	$13→$12
Nov 6, 2025	Canaccord Genuity	Richard Close	PT Raise	Buy	$14→$15
May 12, 2025	Truist Securities	David Macdonald	PT Cut	Buy	$14→$13
May 8, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$14→$13
Feb 27, 2025	Baird	Eric Coldwell	PT Raise	Outperform	$14→$16
Feb 26, 2025	Canaccord Genuity	Richard Close	PT Raise	Buy	$13→$14
Feb 26, 2025	RBC Capital	Ben Hendrix	PT Raise	Outperform	$11→$14
Feb 26, 2025	Truist Securities	David Macdonald	PT Raise	Buy	$12→$14
Feb 13, 2025	UBS	Whit Mayo	PT Cut	Buy	$12→$11
Nov 19, 2024	RBC Capital	Ben Hendrix	PT Cut	Outperform	$13→$11

Analyst Ratings News

PRO
Baird Maintains Outperform on AdaptHealth, Lowers Price Target to $9

Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $10 to $9.

Benzinga Newsdesk

PRO
UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10

UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $8

RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $15 to $8.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $9

Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $9.

Benzinga Newsdesk

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.

Avi Kapoor

PRO
Jefferies Upgrades AdaptHealth to Buy, Raises Price Target to $13

Jefferies analyst Brian Tanquilut upgrades AdaptHealth (NASDAQ:AHCO) from Hold to Buy and raises the price target from $11 to $13.

Benzinga Newsdesk